IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 2005
10/19/2005 5:10:30 PM
PARIS, France--(BUSINESS WIRE)--May 5, 2005--IDM (Immuno-Designed Molecules), a biopharmaceutical company which recently announced a business combination with Epimmune Inc. (Nasdaq : EPMN), will present the results of a phase II trial of its cancer vaccine, Uvidem(R), for the treatment of patients with melanoma, at the Annual Meeting of ASCO (American Society of Clinical Oncology) in Orlando, Florida. This presentation will be given on May 15, 2005, as part of the "Immunotherapy General Poster Session" program, from 8 AM to 12 PM.
Uvidem is a therapeutic vaccine developed by IDM in partnership with Sanofi-Aventis. It consists of dendritic cells loaded with lysates prepared from melanoma cell lines. The phase II trial to be presented included 60 patients with stage IV melanoma and was conducted at 12 clinical centers in France and Australia. The primary endpoint of this trial was to assess the safety and immune response following this treatment.